Optimizing cancer radiotherapy with 2-deoxy-D-glucose: Dose escalation studies in patients with glioblastoma multiforme

Strahlentherapie und Onkologie

Volumn 181, Issue 8, 2005, Pages 507-514

  Singh, Dinesh ^a   Banerji, Ajit K ^b   Dwarakanath, Bilikere S ^c   Tripathi, Rajendra P ^c   Gupta, Jaganath P ^a   Mathew, T Lazar ^c   Ravindranath, Turuga ^c   Jain, Viney ^d  

^a Department of Medical Oncology   (India)

^b Vidyasagar Institute of Mental Health and Neurosciences Hospital   (India)

^c INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

^d WRIGHT STATE UNIVERSITY   (United States)

Author keywords

2 deoxy D glucose; Dose escalation; Glioblastoma multiforme; Radiotherapy; Safety and tolerance

Indexed keywords

DEOXYGLUCOSE; FUROSEMIDE; MANNITOL;

ACUTE TOXICITY; ADULT; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COBALT THERAPY; COMPUTER ASSISTED TOMOGRAPHY; DISORIENTATION; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GAMMA RADIATION; GLIOBLASTOMA; HEADACHE; HUMAN; HYPERHIDROSIS; HYPERTENSION; HYPOGLYCEMIA; HYPOTENSION; HYPOTHERMIA; JOINT STIFFNESS; LETHARGY; MALE; MUSCLE WEAKNESS; NAUSEA AND VOMITING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; POLYDIPSIA; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RESTLESSNESS; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR VOLUME;

ADMINISTRATION, ORAL; ADULT; AGED; BRAIN NEOPLASMS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; COBALT RADIOISOTOPES; DEOXYGLUCOSE; DOSE FRACTIONATION; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; TIME FACTORS;

EID: 23044507635     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-005-1320-z     Document Type: Article

References (60)

1. Alexander E 3rd. Glioblastoma revisited: do clinical observations match basic science theory? Radiosurgery: clinical observations. J Neurooncol 1993;15:169-73.
2. Bernstien M, Rutka J. Brain tumour protocols in North America. J Neurooncol 1993;17:231-51.
3. Birnbaum MJ, Haspel HC, Rosen OM. Transformation of rat fibroblasts by FSV rapidly increases glucose transporter gene transcription. Science 1987;235:1495-8.
4. Dang CV, Semenza GL. Oncogenic alterations of metabolism. Trends Biochem Sci 1999;24:68-72.
5. Dichiro G, Brooks RA, Patronas NT, et al. Issues in the in vivo measurement of glucose metabolism of human central nervouus system tumours. Ann Neurol 1984;15:S138-46.
6. Dwarakanath BS, Adhikari JS, Jain V. Hematoporphyrin derivative potentiate the radiosensitive effects of 2-DG in cancer cells. Int J Radiat Oncol Biol Phys 1999;43:1125-33.
7. Dwarakanath BS, Jain V. Effects of gamma-rays and glucose analogs on the energy metabolism of a cell line derived from human cerebral glioma. Ind J Biochem Biophys 1991;28:203-9.
8. Dwarakanath BS, Jain VK. Modification of the radiation-induced damage by 2-deoxy-D-glucose in organ cultures of human cerebral gliomas. Int J Radiat Oncol Biol Phys 1987;13:741-6.
9. Dwarakanath BS, Jain VK. Energy linked modifications of the radiation response in a human cerebral glioma cell line. Int J Radiat Oncol Biol Phys 1989;17:1033-40.
10. Dwarakanath BS, Singh S, Dube SN, et al. Radiosensitization of Ehrlich ascites tumours by 2-deoxy-D-glucose in Mice. Presented at Radiobiology 2000 - International Conference on Radiation Biology, February 17-19, 2000, Trivandrum, India.
11. Dwarakanath BS, Singh S, Jain V. Optimization of tumour radiotherapy: part V. Radiosensitization by 2-deoxy-D-glucose and DNA ligand Hoechst-33342 in a murine tumour. Ind J Exp Biol 1999;37:865-70.
12. Dwarakanath BS, Zolzer F, Chandana S, et al. Heterogeneity in 2-deoxy-D-glucose-induced modifications in energetics and radiation responses of human tumour cell lines. Int J Radiat Oncol Biol Phys 2001;50:1051-61.
13. Frankenberg-Schwager M, Harbich R, Frankenberg D, et al. 2-deoxy-D-glucose inhibits rejoining of radiation-induced DNA double-strand breaks in yeast. Int J Radiat Biol 1992;61:185-90.
14. Glinski B. Postoperative hypofractionated radiotherapy versus conventionally fractionated radiotherapy in malignant gliomas. A preliminary report on a randomized trial. J Neurooncol 1993;16:167-72.
15. Heesters M, Molenaar W, Go GK. Radiotherapy in supratentorial gliomas. A study of 821 cases. Strahlenther Onkol 2003;179:606-14.
16. Hiraki Y, Rosen OM, Birnbaum MJ. Growth factors rapidly induce expression of the glucose transporter gene. J Biol Chem 1988;263:13655-62.
17. Horton RW, Meldrum BS, Bachelard HS. Enzymatic and cerebral metabolic effects of 2-deoxy-D-glucose. J Neurochem 1973;21:507-20.
18. Hulshof MC, Schimmel EC, Andries Bosch D, et al. Hypofractionation in glioblastoma multiforme. Radiother Oncol 2000;54:143-8.
19. Jain VK, Gupta I, Lata K. Energetics of cellular repair processes in a respiratory-deficient mutant of yeast. Radiat Res 1982;92:463-73.
20. Jain VK, Kalia VK, Gopinath PM, et al. Optimization of cancer therapy: part III. Effects of combining 2-deoxy-D-glucose treatment with gamma irradiation on normal mice. Ind J Exp Biol 1979;17:1320-5.
21. Jain VK, Kalia VK, Sharma R, et al. Effects of 2-deoxy-D-glucose on glycolysis, proliferation kinetics and radiation response of human cancer cells. Int J Radiat Oncol Biol Phys 1985;11:943-50.
22. Jain V, Pohlit W, Purohit SC. Influence of energy metabolism on the repair of X-ray damage in living cells. III. Effects of 2-deoxy-D-glucose on liquid holding reactivation in yeast. Biophysik 1973;10:137-42.
23. Jain VK, Porschen E, Feinendegen LE. Optimization of cancer therapy. Part II. Effects of combining 2-deoxy-D-glucose treatment with gamma irradiation on sarcoma-180. Ind J Exp Biol 1977;15:714-8.
24. Jha B, Pohlit W. Effect of 2-deoxy-D-glucose on DNA double strand break repair, cell survival and energy metabolism in euoxic Ehrlich ascites tumour cells. Int J Radiat Biol 1992;62:409-15.
25. Jha B, Pohlit W. Reversibility of inhibition of DNA double strand break repair by 2-deoxy-D-glucose in Ehrlich ascites tumour cells. Int J Radiat Biol 1993;63:459-67.
26. Kalia VK, Jain VK, Otto FJ. Optimization of cancer therapy. Part IV. Effects of 2-deoxy-D-glucose on radiation-induced chromosomal damage in PHA-stimulated peripheral leukocytes. Ind J Exp Biol 1982;20:884-8.
27. Kern KA, Norton JA. Inhibition of rat fibrosarcoma growth by 2-DG. Surgery 1987;102:380-5.
28. Kerr DS, Hansen IL, Levy MM. Metabolic and hormonal responses of children and adolescents to fasting and 2-DG. Metabolism 1983;32:951-9.
29. Knisely JP, Rockwell F. Importance of hypoxia in the biology and treatment of brain tumour. Neuroimaging Clin N Am 2002;12:525-36.
30. Kortmann RD, Jeremic B, Weller M, et al. Radiochemotherapy of malignant glioma in adults. Clinical experiences. Strahlenther Onkol 2003;179:219-32.
31. Kortmann RD, Jeremic B, Weller M, et al. Immediate postoperative radiotherapy or "watch and wait" in the management of adult low-grade glioma? Strahlenther Onkol 2004;180:408-18.
32. Landau BR, Laszlo J, Stengle J, et al. Certain metabolic and pharmacologic effects in cancer patients given infusions of 2-deoxy-D-glucose. J Natl Cancer Inst 1958;21:485-94.
33. Laszalo J, Harlan WR, Klein RF, et al. The effect of 2-DG infusions on lipid and carbohydrate metabolism in man. J Clin Invest 1960;40:171-6.
34. Latz D, Thonke A, Juling-Pohlit L, et al. Tumour response to ionising radiation and combined 2-deoxy-D-glucose application in Ehrlich ascites tumour bearing mice: monitoring of tumour size and microscopic observations. Strahlentherapie 1993;169:405-11.
35. LENT SOMA tables. Radiother Oncol 1995;35:17-60.
36. Lutterbach J, Sauerbrei W, Guttenberger R. Multivariate analysis of prognostic factors in patients with glioblastoma. Strahlenther Onkol 2003;179:8-15.
37. McAleese JJ, Stenning SP, Ashley D, et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched pair survival analysis with MRC controls. Radiother Oncol 2003;67:177-82.
38. McComb RB, Yushok WD. Metabolism of ascites tumour cells III effects of 2-deoxy-D-glucose phosphorylation on phosphorous metabolism. Cancer Res 1964;24:193-7.
39. Merall NW, Plevin R, Gould GW. Growth factors, mitogens, oncogenes and the regulation of glucose transport. Cell Signal 1993;5:667-75.
40. Mohanti BK, Rath GK, Anantha N, et al. Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical trial on human cerebral glioma. Int J Radiat Oncol Biol Phys 1996;35:103-11.
41. Nieder C, Andratschke N, Widenmann N, et al. Radiotherapy for high-grade gliomas. Does altered fractionation improve the outcome? Strahlenther Onkol 2004;180:401-7.
42. Padma MV, Said S, Jacobs M, et al. Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol 2003;64:227-37.
43. Purohit SC, Pohlit W. Experimental evaluation of the glucose antimetabolite, 2-deoxy-D-glucose (2-DG), as a possible adjuvant to radiotherapy of tumours. I. Kinetics of growth and survival of Ehrlich ascites tumour cells (EATC) in vitro and growth of solid tumours after 2-DG and X-irradiation. Int J Radiat Oncology Biol Phys 1982;8:495-9.
44. Salazar OM, Rubin P, Feldstein ML, et al. High dose radiation therapy in the treatment of malignant gliomas: final report. Int J Radiat Oncol Biol Phys 1979;5:1733-40.
45. Shim H, Dolde C, Lewis BC, et al. c-Myc transactivation of LDH-A: implication for tumour metabolism and growth. Proc Natl Acad Sci USA 1997;94:6658-63.
46. Singh D, Banerjee AK, Dwarakanath BS, et al. Studies with 2-deoxy-D-glucose as an adjuvant in the radiotherapy of glioblastoma multiforme. Proceeding of the 32nd Annual Meeting of the European Society for Radiation Biology (ESRB), Liege, Belgium, September 4-7, 2002.
47. Singh SP, Singh S, Jain V. Effects of 5-bromo-deoxy-uridine and 2-deoxy-D-glucose on radiation-induced micronuclei in mouse bone marrow. Int J Radiat Biol 1990;58:791-7.
48. Storer BE. Design and analysis of phase I clinical trials. Biometrics 1989;45:925-37.
49. Suit HD, Baumann M, Skates S, et al. Clinical interest determinations of cellular radiosensitivity. Int J Radiat Biol 1989;56:725-37.
50. Surawicz T, Davis F, Freels S, et al. Brain tumour survival: results from the National Cancer Data Base. J Neurooncol 1998;40:151-60.
51. Swamy RK, Manickam J, Adhikari JS, et al. The glycolytic inhibitor 2-deoxy-D-glucose does not enhance radiation-induced apoptosis in mouse thymocytes and splenocytes in vitro. Ind J Exp Biol 2005:43(in press).
52. Thompson DA, Lilavivathana U, Campbell RG, et al. Thermoregulatory and related responses to 2-deoxy-D-glucose administration in humans. Am J Physiol 1980;239:R-291-5.
53. Timperley WR. Glycolysis in neuroectodermal tumours. In: Thomas DGT, Graham DI, eds. Brain tumours. Scientific basis, clinical investigation and current therapy. London: Butterworth's 1980:145-67.
54. Warburg O. On the origin of cancer cells. Science 1956;123:309-14.
55. Weber G. Enzymology of cancer cells. N Engl J Med 1977;296:541-51.
56. Weinhouse S. Glycolysis, respiration, and anomalous gene expression in experimental hepatomas. Cancer Res 1972;32:2007-16.
57. Woodward GE, Hudson MT. The effect of 2-deoxy-D-glucose on glycolysis and respiration of tumour and normal tissues. Cancer Res 1954;14:599-605.
58. Yang X, Darling J, McMillan T, et al. Radiosensitivity, recovery and dose rate effect in three human glioma cell lines. Radiother Oncol 1990;19:49-56.
59. Younes M, Lechago LV, Somoano JR, et al. Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. Cancer Res 1996;56:1164-7.
60. Zulch KJ. Principles of the new World Health Organization (WHO) classification of brain tumours. Neuroradiology 1980;19:59-70.